Earth Science Tech, Inc. (ETST) Eyes Uplisting to OTCQB, Retains Counsel for Planned Regulation A+ Tier 2 Financing

  • Goal is to raise $4 million to help company finance its planned projects
  • Expansion into Canada eyed, attorney retained to help seek Canadian licenses to import ETST’s CBD-rich hemp oil into country
  • ETST would also use funding for MSN-2, its home kit for the detection of sexually transmitted diseases

Earth Science Tech, Inc. (OTC: ETST) is working toward an uplisting to the OTCQB Venture Market in early 2018. It has also retained counsel for a planned Regulation A+ Tier 2 round of financing, which the company hopes will raise an aggregate of $4 million (http://cnw.fm/W8I2d). The funds would be used to finance its planned projects in the new year and for general working capital (http://cnw.fm/Pi0hl), with share cancellation by company founders counteracting dilution.

ETST is also eyeing expansion into Canada in 2018, and it has appointed an attorney who will serve as consultant for ETST’s activities in that country, Avi Levi, Esq. (http://cnw.fm/aW8ww). He will help the company apply for licenses to import its CBD-rich hemp oil into Canada. It will then be exported to various countries as raw hemp oil or in individual ready-to-consume bottles, the company said.

Dr. Michel Aube, CEO and chief scientific officer of the company, said, “With the funds being raised through the Regulation A+ offering, we will be in a position to begin finalizing all of our projects while we pursue grants from the Canadian government to cover our MSN-2 medical device, CBD patent pending formulas and CBD based generic pharmaceutical drugs.”

The MSN-2 device is prepared for third-party evaluation ahead of manufacture and commercialization. The MSN-2 device is a home kit designed for the detection of sexually transmitted diseases.

ETST is a biotechnology company operating in the fields of hemp cannabinoid pharmaceutical, nutraceutical, and medical device R&D. Its hemp CBD is made using the liquid extraction process. As a result, its CBD oil is 100 percent natural and organic, as noted by the company.

ETST has three wholly owned subsidiaries. First, Earth Science Pharma, Inc. specializes in the development of medical devices for the treatment of sexually transmitted diseases. Second, Cannabis Therapeutics, Inc. works to explore the medicinal powers of CBD. Cannabis Therapeutics holds a provisional application patent for a CBD product which develops treatments for ovarian and breast cancers. Third, KannaBidioid, Inc. focuses on the recreational cannabis space.

For more information, visit the company’s website at www.EarthScienceTech.com

More from CannabisNewsWire

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.net

EVIO, Inc. (EVIO) is Exceeding Expectations

  • Investor interest nearly doubles size of placement
  • Company’s 2017 revenues soared 438 percent year-over-year
  • On pace to double number of testing facilities this year

The regulatory uncertainties surrounding cannabis will have little impact on the long-term growth of the industry. There’s overwhelming scientific evidence validating the medical efficacy of certain cannabinoids and, like all medications, cannabinoids require quality control assurances for potency and purity.  Also, much like prohibition, it’s realistic to expect parochial federal regulators to ultimately succumb to the will of the majority and relax any uncertainties around recreational cannabis use. Again, the end product must be tested and screened for potency and any potentially harmful byproducts.

EVIO, Inc. (OTCQB: EVIO) is the established national leader in such testing and verification, providing accredited cannabis testing, as well as high-quality analytical and consulting services for agricultural and biomedical industries in the United States. Operating coast-to-coast, the company’s EVIO Labs division provides state-mandated ancillary services to ensure both safety and quality of the nation’s cannabis supply. The company provides state-of the-art analytical testing and advisory services, and it performs extensive product research in its accredited laboratory testing facilities.

In a recent vote of confidence for EVIO, as well as in the long-term viability and opportunities in the cannabis industry, EVIO just closed a $5,973,000 private placement. The initial target of $3 million was nearly doubled due to investor interest in EVIO’s uniquely scalable business model and scientific expertise in the cannabis testing space (http://cnw.fm/GaCw2).

Market savants fully understand that fresh capital seldom flows to dead-end deals, and doubling the raise is a significant signal of potential success. The best-efforts offering was completed on January 30 through lead agent and bookrunner Dominick Capital Corporation of Toronto, Canada.

As further evidence of EVIO’s growth curve, the company reported a 438 percent revenue increase on a year-over-year basis in its fiscal year ended September 30, 2017 (http://cnw.fm/ZtN6O). The vast majority of this growth came from increased testing revenue, which was up 782 percent, while consulting services increased by 27 percent.

EVIO has grown from one laboratory in Oregon to nine fully operational laboratories in California, Colorado, Florida, Massachusetts and Oregon, and it intends to open 18 laboratory facilities at other locations around the United States by the end of 2018.

For more information, visit the company’s website at www.EVIOLabs.com

More from CannabisNewsWire

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.net

Recent Report on PotNetwork Holding Inc. (POTN) Share Price Target Highlights Encouraging Data

  • Heightened share price target for PotNetwork Holding Inc. set at $1.25
  • Previous market estimates, exceeded by over 70 percent, show positive month-to-month sales for PotNetwork Holdings Inc.
  • SeeThruEquity report highlights the greatly lowered legal and physiological risk from hemp-derived CBD

A recent comprehensive report by SeeThruEquity highlighting PotNetwork Holding Inc. (OTC: POTN) and its subsidiary, Diamond CBD, projected a heightened share price target set at $1.25. The increase was attributed to the company’s strong monthly sales data and 3Q17 filings (http://cnw.fm/A2krk). Per the report, these indicated “continued profitability as the company invests in growth.”

In a prior news release, Dr. Richard Goulding, CEO of PotNetwork Holding Inc., stated, “It is very rewarding to experience this type of growth and success, and all the more pleasing to see an acknowledgement of our collective efforts in the marketplace.”  This statement followed news that the company’s previously announced estimates of $8.3 million were exceeded by over 70 percent, reaching $14.5 million due to rapid month-to-month growth in sales (http://cnw.fm/Rt1p8).

SeeThruEquity’s report highlighted that hemp derived from CBD can provide a legal alternative to marijuana-based CBD, which is banned by federal law. This allows consumers to make use of CBD products without the risk of experiencing a ‘high’ or infringing on government law. The projected market for hemp-derived CBD is expected to grow at a CAGR of roughly 53 percent through 2020, positioning it among the fastest-growing segments within the multi-billion dollar legal cannabis and hemp market.

Cannabidiol (CBD) and tetrahydrocannabinol (THC) are the most researched derivatives of cannabis, a psychoactive drug also known as marijuana (http://cnw.fm/u83jV).  The traditional ‘high’ associated with this drug is largely thanks to the presence of THC, and, while CBD is a structural isomer of THC (meaning that it has the same chemical composition), the atomic structure is arranged differently, offering many of the same health benefits without the psychoactive effects of THC. Based on numerous studies, CBD has demonstrated the capacity to produce a number of effects on the endocannabinoid system (ECS), including boosting immune system function, reducing sensations of pain, playing a role in inflammatory response and altering appetite, mood, memory and energy levels.

With the advancement of technology and ongoing research of the medicinal qualities of CBD, it is possible that these products could, potentially, serve as substitutes for harmful medications that are currently on the market.  The natural healing properties are being assessed on a global level, and several journals have already noted the economic impact of CBD in general. Matt Karnes of Greenwave Advisors, in an interview with Forbes, stated, “In terms of the CBD market size, I estimate an almost $3 billion market by 2021. Right now, there are 15 states that allow CBD only — this is in addition to the 28 states plus DC that have legalized medical marijuana.”

Numerous studies on the positive effects of cannabinoids and THC have paved the way for legalization of marijuana for medicinal purposes in Canada and the U.S.  A focus report by Mackie Research Capital Corp. (http://cnw.fm/Dgh2g) notes that (based on internal models) the Canadian marijuana market is expected to increase in size quickly, with the forecast peak in market size to exceed C$2.5 billion by 2020. With the United States presenting various states in which medicinal marijuana is legal, the market size for these states (most notably Colorado, Arizona, Oregon and Michigan) is projected to record a significant increase in growth from 2015 to 2020. For the above-mentioned states, the Colorado market is expected to reach more than $1.5 billion, Arizona is expected to exceed $453 million, Oregon could increase to $330 million and Michigan is expected to rise to $556 million, all by 2020.

PotNetwork Holding Inc. is a publicly traded company that acts as a holding company for a number of subsidiaries, namely First Capital Venture Co., PotNetwork.com, and Diamond CBD, Inc.  The latter focuses on research, development and multinational marketing of hemp extracts containing a wide variety of cannabinoids and natural hemp derivatives.  Diamond CBD’s team of hemp industry pioneers, chemists, doctors, scientists and natural product experts aims to produce high-grade CBD oil, providing a variety of CBD oils, tinctures, edibles and vape liquids.

In a previous news release (http://cnw.fm/6q5VV), Goulding added, “[W]e are proud, and think our shareholders should be too, that on December 13, 2017 PotNetwork Holding was named by Huffington Post, a prominent major national news source, as “One of Five Notable CBD Revolution Industry Leaders’, an accolade that pays tribute to the company’s achievements and future prospects.”

Goulding further noted, “2017 has been a phenomenally successful year for us! Our unprecedented sales growth pays tribute to the hard work of our staff and our resellers, and the exceptional quality of our CBD product line which expanded greatly over 2017.” He also emphasized that the company is poised for growth during 2018 and it embarks on new and unique marketing initiatives and embraces new opportunities.

Without question, the recent report by SeeThruEquity highlighting PotNetwork Holding Inc. and Diamond CBD projects not only an increased share price target, but also a positive expansion of the company within this multi-billion dollar arena.  With an ever-increasing demand for safer products of this nature that abide by all governing regulations, PotNetwork Holding Inc., also with its subsidiaries, has its foot in the door of tomorrow’s market.

For more information, visit the company’s website at www.PotNetworkHolding.com

Pursuant to the applicable federal law, the sale or distribution of CBD with less than 0.03% of tetrahydrocannabinol by retailers may be permissible in all states.  However, the local, state and federal laws regarding these issues tend to remain in flux and should be accordingly reviewed by local counsel and, as such, legal advice is not intended, but specifically disclaimed.

More from CannabisNewsWire

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.net

Teewinot Life Sciences’ Patented Biosynthetic Tech Cuts Costs and Produces Clinical-Grade Cannabinoids

  • Company’s IP portfolio, including proprietary technology and biosynthetic methods, features seven U.S. patents and patent filings in numerous other key countries around the world
  • Eliminating the high costs of cultivating plants, Teewinot Life Sciences Corporation delivers pure, consistent pharmaceutical-grade cannabinoids
  • Company’s goal is to cut costs and approach cannabinoid production like a pharmaceutical company, not as a cannabis firm

Teewinot Life Sciences Corporation has an advantage in consistently producing pure, clinical-grade cannabinoids with its patented biosynthetic technology. The results eliminate the watering and electrical costs of traditional plant cultivation, as well as the variances in quality. Instead, its method offers low-cost cannabinoids in a pure, consistent clinical grade.

Teewinot Life Sciences is a Tampa, Florida-based global biopharmaceutical company focused on cannabinoid clinical development utilizing patented and proprietary synthetic biology and biocatalysis technology. Its strategy involves the production and use of cannabinoid molecules. The goal of the company is to produce, at lower cost, consistent and pure cannabinoids that it believes can be used to develop superior human therapies.

The company and its wholly-owned subsidiaries have patented technologies that produce individual cannabinoids at commercial scale for a wide variety of markets. It approaches the process as a straight medical company, not as a marijuana firm. Its process involves the pharmaceutical manufacture of cannabinoids through biocatalysis and synthetic biology.

Cannabinoid biosynthetic enzymes are produced in microorganisms transformed with cannabinoid biosynthetic genes. Those enzymes are then used to manufacture pharmaceutically-pure cannabinoids.

The goal is to improve human therapies. The company has now secured seven U.S. patents and has a portfolio of patent applications in a number of countries. Teewinot Life Sciences has subsidiaries in Ireland and Canada.

For more information, visit the company’s website at www.TLSCorp.com

More from CannabisNewsWire

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.net

ChineseInvestors.com, Inc. (CIIX) Offering Innovative Access to Cryptocurrency

  • Despite China’s ban on cryptocurrency, CIIX is positioned to lead the way in cryptocurrency education and awareness for the Chinese-speaking community
  • Demand for bitcoin continues to rise despite China’s ban on cryptocurrency
  • Company is committed to the education and growth of cryptocurrency and providing innovative ways of making bitcoin more accessible

ChineseInvestors.com, Inc. (OTCQB: CIIX) is continuing its commitment to cryptocurrency education and awareness for the Chinese-speaking community. Its educational services seek to answer the average person’s curiosity while simultaneously providing skilled investors with up-to-date news on digital currency. Using the Chinese language character sets, CIIX provides analysis and education that is accessible to the Chinese-speaking community worldwide. CIIX provides information on how to purchase bitcoin, real-time market commentary and consulting services, as well as advertising and public relations services.

Cryptocurrency is appealing in that it allows investors to diversify their portfolios. This shift away from traditional investment opportunities brings with it an air of excitement. Bitcoin is being exchanged by investors in unregulated offline platforms in an effort to bypass China’s ban (http://cnw.fm/D3Hxq). The scarcity of bitcoin, and the complexity of mining new coins, is part of the draw. Despite a recent post by China’s Communist Party paper bashing bitcoin and insisting that cryptocurrency is a load of hype, demand has continued to rise (http://cnw.fm/jA6Le).

CIIX is committed to raising awareness and education surrounding bitcoin. The company now hosts a daily broadcast from the NYSE, titled ‘Bitcoin MultiMillionaire’, with the intent of educating Chinese-speaking viewers on the most current news in cryptocurrency. In addition, CIIX is committed to bitcoin growth and has installed a bitcoin ATM in the lobby of its headquarters in San Gabriel, California. The Chinese middle and upper class is growing and looking for new ways to diversify their portfolios. ChineseInvestors.com is ready and able to offer them innovative accessibility to cryptocurrency.

For more information, visit the company’s website at www.ChineseInvestors.com

More from CannabisNewsWire

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.net

Skinvisible, Inc. (SKVI), Quoin Pharmaceuticals Proposed Merger to Address Opioid Pain Management Market

  • A merger between Skinvisible and Quoin will enable a successful entry on the post-surgical pain management market
  • Opioids – which typically refer to oxycodone, hydrocodone, and fentanyl – are highly addictive painkillers; nearly three in 10 Americans prescribed opioids for chronic pain will abuse them
  • Opioids are becoming increasingly deadly to Americans; in 2016, two-thirds of drug-related deaths involved opioids; in fact, since 1999, opioid-related deaths in the United States have increased nearly fourfold
  • Drug abuse is a burden shared by every state; nearly 63,600 Americans lost their lives to drug overdoses in 2016 – a 21 percent increase over the previous year; from 2000 to 2016, the U.S. Centers for Disease Control and Prevention estimates that more than 600,000 people died from drug overdoses in the United States
  • Every 25 minutes, a baby in the United States is born suffering from opioid withdrawal

Skinvisible, Inc. (OTCQB: SKVI) previously announced the signing  of a Letter of Intent for a proposed merger with Quoin Pharmaceuticals Limited – a partnership that could address significant unmet medical needs on the pain management market. If both parties agree on the terms, the merger should be completed this year, and the resulting entity will operate under the name Quoin Pharmaceuticals Inc. and will continue to trade on the OTCQB market.

Quoin’s strength is within the area of pharmaceutical product development for products that address some of the most serious present-day health problems. Skinvisible is the developer of innovative delivery system technologies that can enhance product delivery and performance.

Quoin’s lead product is QRX001 – a transdermal NMDA receptor antagonist for the effective treatment of pain following surgery.  QRX001 delivers up to 72 hours of effective pain relief after surgical interventions.  Almost 30 clinical studies have been performed to date on the NMDA receptor antagonist, clearly showing that sub-anesthetic doses reduced 24-hour PCA morphine consumption; reduced post-operative nausea and vomiting; reduced pain intensity; resulted in adverse events that were mild or absent; and generated better results than any other single product or combination. The aim of the product is to also reduce the use of opioids for pain management following an operation.

Upon the product’s launch, QRX001 is expected to provide surgeons with a new and effective alternative to opioids. Opioid abuse has reached an epidemic level in the U.S., with opioid overdoses causing more than 90 deaths per day (http://cnw.fm/7vtpP). This number has grown exponentially in the past decade, according to the Centers for Disease Control and Prevention, with opioid use remaining widespread despite the risks. Today, approximately 12 million Americans report that they use pain killers in a non-medicinal way.

The opioid market in the U.S. is estimated at $6 billion annually.  With the opioid epidemic now deemed a National Health Emergency, there is a significant push to find new products that reduce or eliminate their use, particularly in a post-surgical setting, which is where 50 percent of people who become addicted first become exposed to these drugs.

In addition to wrecking lives, opioid abuse poses a massive burden on the economy. Adding up money lost from costs related to health care, addiction treatment, reduced work productivity and crime, the Centers for Disease Control and Prevention estimates that the economic burden of the opioid crisis is more than $78.5 billion per year.

Almost half of the victims were first introduced to opioids after undergoing surgery. According to the National Center for Health Statistics, 100 million surgeries take place in the U.S. every year (http://cnw.fm/k4cxW). At least 50 million of these surgical interventions necessitate the use of post-operative pain management pharmaceuticals.

Currently, the pain management market in the U.S. is fueled by a number of sectors. The most prominent ones include post-operative pain relief, arthritis pain, cancer pain, migraine and neuropathic pain. As larger Western populations age and become susceptible to an array of medical conditions, the need for new pain management developments will grow even further. The partnership between Skinvisible and Quoin perfectly positions the two companies to address these growing unmet needs on the pain management market.

The Skinvisible announcement states that new technologies and product synergies between the two companies could potentially provide significant value to shareholders after the merger. Together, Skinvisible and Quoin could maximize their product development opportunities, as noted by Skinvisible President Terry Howlett.  The official news release also included a disclaimer regarding ‘forward looking’ statements.

For more information, visit the company’s website at www.Skinvisible.com

More from CannabisNewsWire

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.net

Regulation and Oversight of Virtual Currencies by SEC and CFTC Agencies to be Reviewed, Congressional Hearing Set

  • The Committee on Banking, Housing and Urban Affairs sets hearing for February 6 to review oversight role of the SEC and CFTC over virtual currencies, such as bitcoin
  • In an op-ed written jointly by the SEC and CFTC, agency chiefs say they would support policy efforts to revisit framework of their cryptocurrency regulation; both will testify before the committee
  • Agencies say they will seek to maintain integrity and transparency in the volatile cryptocurrency markets; goal is to protect all market participants and investors

Virtual currency oversight by the Securities and Exchange Commission (SEC) and the U.S. Commodity Futures Trading Commission (CFTC) will be reviewed after the heads of both agencies testify on February 6 before a hearing of the Committee on Banking, Housing and Urban Affairs (http://cnw.fm/Aqb3b).

Jay Clayton, chairman of the SEC, and J. Christopher Giancarlo, chairman of the CFTC, will testify at the hearing. What they will say was telegraphed in their recent jointly-authored op-ed (http://cnw.fm/sb3DN). In it, they noted that most check-cashing and money transmission services are state regulated. They argue that most of the internet-based cryptocurrency trading platforms have registered as payment services and, therefore, are not subject to direct regulation today by the two federal agencies.

Their op-ed said, “Many of the internet-based cryptocurrency trading platforms have registered as payment services and are not subject to direct oversight by the SEC or CFTC. We would support policy efforts to revisit these frameworks and ensure they are effective and efficient for the digital era.”

The agencies said they seek market integrity and transparency. In the op-ed, they note that they seek review of their oversight of these markets and would continue to work with law enforcement to enforce this goal. “The CFTC and SEC, along with other federal and state regulators and criminal authorities, will continue to work together to bring transparency and integrity to these markets and, importantly, to deter and prosecute fraud and abuse,” they added.

More from CannabisNewsWire

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.net

Global Hemp Group, Inc. (CSE: GHG) (FRANKFURT: GHG) (OTC: GBHPF) is “One to Watch”

  • U.S. hemp retail market estimated at $1.8 billion by 2020 with 22% CAGR
  • Global hemp-based cannabidiol (CBD) segment projected to reach $3 billion by 2021
  • Disruptive potential for industrial hemp products offers substantial rewards

Global Hemp Group, Inc. (CSE: GHG) (FRANKFURT: GHG) (OTC: GBHPF), headquartered in British Columbia, Canada, is a publicly traded company founded in 2014. Global Hemp Group is focused on acquiring and developing a strategic portfolio of like-minded companies that believe in the significant potential of the industrial hemp plant. Global Hemp Group’s focused on attracting joint venture partners across all sectors of the industrial hemp industries with the commitment to improve quality of life by researching, developing and distributing sustainable materials, products and services produced from hemp.

The company’s mission is to build a strategic portfolio of hemp-based companies that operate synergistically to consistently deliver a solid ROI to its shareholders. Global Hemp Group has established the concept of Hemp Agro-Industrial Zone (HAIZ) (https://globalhempgroup.com/hempagro/) in order to build cooperative mechanisms across industrial sectors with a focus on different parts of the hemp plant. Under the HAIZ strategy, Global Hemp Group brings together capital, farmers and labor in an effort to build a “soil-to-shelf” portfolio of complimentary companies and joint venture partners in the global hemp industry.

Global Hemp Group has chosen to only work with suppliers of high quality, sustainable raw materials and finished products derived from the hemp plant. Among the leading industries utilizing industrial hemp’s exceptional properties is the automotive sector, building materials market, bio-composites, energy-related markets, super-foods, nutritional supplements, nutraceuticals and the cannabinoid markets. Guided by the principal theme of “global environmental stewardship,” Global Hemp Group focuses on the key concepts of sustainability and social responsibility in all its endeavors.

Global Hemp Group’s joint venture with publicly traded Marijuana Company of America on hemp cultivation trials in 2017, designed to develop commercial hemp production on the Acadian peninsula of New Brunswick, Canada, for the first time in 20 years, was a great success. The partners are preparing for the upcoming changes in Canada’s cannabis legislation that will permit cannabinoid extraction from industrial hemp. Farmers have already been recruited to plant a minimum of 125 acres of industrial hemp for the 2018 growing season, with the goal of increasing the acreage under cultivation to 1,000+ acres by year three of the joint project. Global Hemp Group is preparing an application for a processing license to extract cannabidiol (CBD) and other cannabinoids from the upcoming industrial hemp crop. Discussions are also underway with potential processing partners for the extraction of cannabinoids and straw processing for building materials for the upcoming harvest in October 2018, with a longer term plan to establish permanent processing facilities by October 2019.

Global Hemp Group is led by Charles Larsen as its president, CEO and chairman of the board. Larsen’s more than 30 years of experience working in government, public, private and startup companies as an executive manager includes being the founding president of Medical Marijuana, Inc., the first public company in the Cannabis space. Larsen is also a founder and current director of Marijuana Company of America, Inc., and has been actively involved in the cannabis and hemp industry for nearly a decade. Larsen is joined by Curt Huber, who serves as CFO and director. Huber is an independent corporate and financial consultant with more than 25 years of experience in all facets of public companies among many different sectors including mining, oil and gas, and technology.

Also joining the management team as director is Dr. Paul T. Perrault, an agricultural economist trained in cooperative development and in rural development. Perrault’s experience includes years of consulting on rural development projects introducing new crops in several developing countries and strengthening agricultural research organizations, principally in Africa. Jeff Kilpatrick also serves as a director and is currently a program supervisor of Alachua County Department of Court Services in Gainesville, Florida. Kilpatrick, who spent 21 years in the U.S. Coast Guard, is a member of LEAP – Law Enforcement Against Prohibition – and is president elect for the National Association of Pretrial Services Agencies (NAPSA).

Global Hemp Group’s business philosophy is “A healthier future through sustainable business strategies.”

For more information, visit the company’s website at www.GlobalHempGroup.com

More from CannabisNewsWire

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.net

Riot Blockchain, Inc. (NASDAQ: RIOT) Investments Solidify Effort to Build Decentralized Tech Platforms

  • Company’s investments in Verady, Coinsquare and TessPay among recent work to increase security for transactions
  • Blockchain, cannabis sectors accounted for nearly 10 percent of rising daily activity for TD Ameritrade in 4Q2017
  • Estimated $10 billion in cryptocurrency transacted each day

Riot Blockchain, Inc. (NASDAQ: RIOT) is advancing its focus on the rising blockchain technology and its cryptocurrency applications, as exemplified by its November announcement of its strategic investment in Verady, LLC, a company that provides accounting, auditing and verification for blockchain-based assets such as cryptocurrencies (http://cnw.fm/lNMe5). The strategy paid off with news that Riot Blockchain’s stock surged from $7 in November to more than $46 in a month, and the company remains committed to gaining “exposure to the blockchain ecosystem through targeted investments in the sector.”

Riot’s primary focus is on the bitcoin and Ethereum cryptocurrencies, and the company owns a share in Coinsquare, a Canada-based cryptocurrency exchange, as well as a majority share in TessPay, which serves as a blockchain-enabled payment vehicle for wholesale telecom carriers. Despite fluctuations in the value of bitcoin as the stock reached stratospheric levels following a hard-charging yearlong rally, and amid ongoing concerns in some sectors that its value is being propped up (http://cnw.fm/4txgW), bitcoin’s price remains exponentially above the value of an ounce of gold, which it passed last March.

A NetworkNewsWire article about the popularity of blockchain and cannabis-related stocks cited TD Ameritrade in reporting that daily average trades for the last quarter of 2017 were up 49 percent from the previous year, with trades in the blockchain and cannabis sectors accounting for between six and nine percent of daily activity (http://cnw.fm/nrQr1). Verady’s website (www.Verady.com) notes that over $10 billion worth of cryptocurrency changes hands each day in transactions worldwide, with no framework for proper tracking, reconciliation or reporting. “Audit and Accounting Standards haven’t caught up,” it states, citing its mission to provide the auditing and accountability services for major cryptocurrency companies. In December, Verady announced a strategic partnership with Georgia-based accounting organization Acuity and launched its VeraNet platform as it worked on a convergence of cryptocurrency wallet data with traditional accounting tools for businesses (http://cnw.fm/y3Ubd).

John O’Rourke, chairman and CEO of Riot Blockchain, referred to the company’s acquisition of a stake in Verady as continuing its commitment to building blockchain technologies as a first mover on the NASDAQ focused on those technologies. Verady stated that it will use the investment to strengthen itself by advancing its technology and increasing the size of its team. On January 30, the company announced its appointment of cybersecurity expert and strategic executive Christopher Ensey as COO. As the former COO of Dunbar Security Solutions, Ensey managed over 150 security professionals across physical and digital operations while capturing over 100 mid to large enterprise clients (http://cnw.fm/7DBVb). On January 17, the company appointed experienced blockchain data mining manager Jeffrey Vormittag as the COO of its wholly owned subsidiary, Riot Blockchain Canada Inc.

The blockchain is a decentralized and encrypted ledger system established to ensure the security and verifiability of transaction records without the need for intermediaries, which came to include banks as the popularity of blockchain-based cryptocurrencies began to rise. Blockchain “miners” work under an international system set up to establish a “proof of work” verification protocol. Riot Blockchain perceived the potential of the technology early on and, in October, redesigned its brand as it began work to establish an advisory board that has sufficient technical experience to help it become a leading authority and supporter of blockchain.

For more information, visit the company’s website at www.RiotBlockchain.com

More from CannabisNewsWire

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.net

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Enters Agreement with Cannabis-Infused Edibles Manufacturer

  • Lexaria enters agreement with Cannfections to develop an innovative range of cannabis-infused chocolates and gummies incorporating its proprietary technology, DehydraTECH™
  • Cannfection’s formulation and manufacturing expertise can be offered to other Lexaria licensee partners
  • The agreement is expected to generate new cannabis-based edible products for domestic and international markets

On January 25, 2018, Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX) announced that it had entered into a seven-year agreement with Cannfections Group Inc. to provide its patented DehydraTECH™ technology for the development of a new range of cannabis-infused chocolates and gummies (http://cnw.fm/Hef3A). Cannfections is a new company, established by one of Canada’s leading chocolate manufacturers with over 85 years of experience in the production of high-quality chocolate and confectionery products for several prominent domestic and international chocolate brands. Cannfections is a pending entrant to the Licensed Producer program for cannabis-infused products.

Under this agreement, Lexaria is able to offer other licensee partners the use of Cannfections’ formulation and manufacturing expertise for the production of cannabis-infused chocolates and gummies, powered by Lexaria’s patented DehydraTECH™ delivery technology. This is expected to generate new product entries for Canadian cannabis edibles for the domestic market, as well as the growing number of international markets.

DehydraTECH™ is a patented, cost-effective and proven delivery technology that enhances the taste, smell, speed of action, bioabsorption and bioavailability of beneficial compounds in ingestible products. This technology has been awarded patents in the United States and Australia, and it has patents pending in 44 other countries. Lexaria is the only company in the world with a patent for the oral delivery of all non-psychoactive cannabinoids, such as cannabidiol (CBD). Lexaria’s patents involve the use of its proprietary technology for oral delivery of an extensive range of lipophilic active compounds, including cannabinoids, non-steroidal anti-inflammatory drugs (NSAIDs), vitamins and nicotine.

Lexaria’s proprietary DehydraTECH™ technology masks recognition of the flavor and odor of compounds by oral and olfactory receptors. It enables manufacturers to create healthier, low-sugar products by eliminating the sugars and sweeteners traditionally used in product formulations to mask bitter tastes and unpleasant smells. This technology also increases the bioabsorption of cannabinoids and other active ingredients by up to 10 times. While other delivery technologies typically take between 60 and 120 minutes to take effect, DeydraTECH™ has been proven to register the onset of effects within 15 to 20 minutes.

Consumers benefit significantly from the enhanced taste of edibles and the reduced time to effect. As a disruptor in the growing cannabis market, Lexaria’s technology can either reduce the cannabinoid per serving unit cost, or deliver stronger effects where serving levels are regulated. The company’s technology can be applied to the manufacture of diverse product dosage forms, including foods, emulsions, liquids, tablets and capsules. Lexaria has produced a range of products for testing, demonstration and sales. These include CBD tablets, protein energy bars, exotic teas and TurboCBD, a high-absorption hemp oil capsule containing ginseng and ginkgo.

Lexaria has signed several royalty agreements for the use of its proprietary delivery technology with companies in Canada and the United States. Its latest venture with Cannfections is another step in the company’s ongoing pursuit of strategic partnerships with leading global companies to expand adoption of its innovative technology and deliver increased value for shareholders.

For more information, visit the company’s website at www.LexariaEnergy.com

More from CannabisNewsWire

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.net